SUO 2016: Immunotherapy for Prostate Cancer: What is the Way Forward? - Session Highlights

San Antonio, Texas USA ( Immunotherapy treatment for prostate cancer has been quite limited given that currently Sipuleucel-T is the only immunotherapy approved for the management of castrate resistant prostate cancer. With the introduction of check-point inhibitors there has been a growing interest in the use of this type of therapies in patients with advanced prostate cancer.

SUO 2016: SLCO2B1: Biology & Therapeutic Implications - Session Highlights

San Antonio, Texas USA ( Dr. Harshman presented original research that studied the influence and manipulation of the SLCO2B1 transporter in prostate cancer treatment. SLCO2B1 is a gene that encodes a sodium-independent organic anionic transporter that is responsible for mediating the transport of a variety of hormones and drugs into cells.

SUO 2016: Potential Therapeutic approaches to neuroendocrine prostate cancer - Session Highlights

San Antonio, Texas USA ( Castrate resistant small cell/neuroendocrine prostate cancer (NEPC) is a clinically aggressive variant of prostate cancer. It usually has low or stable PSA and usually metastasizes to visceral organs.

SUO 2016: EAU Lecture: ProtecT trial - Session Highlights

San Antonio, Texas USA ( Prostate cancer is a global and common problem. The ProtecT trial was designed to assess the effectiveness of active monitoring (AM), radical prostatectomy (RP) and radiation for localized prostate cancer diagnosed by a PSA testing program.

SUO 2016: Targeting DNA repair pathways in prostate cancer - Session Highlights

San Antonio, Texas USA ( Human cells have several methods for DNA repair such as single strand repair of base pair mismatch repair. These methods are heavily involved in the malignant process and provide potential targets for treatment of cancer in general and prostate cancer specifically.

SUO 2016: Mechanisms of Resistance to AR: AR Variants and GR - Session Highlights

San Antonio, Texas USA ( Dr. Arora presented original research demonstrating a new understanding of the resistance patterns to AR inhibition in castration-resistant metastatic prostate cancer (mCRPC).

SUO 2016: Prevalence and prognostic significance of circulating tumor cells in clinically localized prostate cancer - Session Highlights

San Antonio, Texas USA ( Simpa Salami, University of Michigan, discussed circulating tumor cells (CTC) in localized prostate. There is a potential to extend research beyond CTC numeration and the objective of this study was to assess CTC significance in high risk prostate cancer.
Page 1 of 4

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.